These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31005950)

  • 1. Effect of metformin on clinical and biochemical hyperandrogenism in adolescent girls with type 1 diabetes.
    Hafez M; Musa N; Elbehairy S; Atty SA; Elbarbary M; Amin M
    J Pediatr Endocrinol Metab; 2019 May; 32(5):461-470. PubMed ID: 31005950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus.
    Codner E; Iñíguez G; López P; Mujica V; Eyzaguirre FC; Asenjo S; Torrealba I; Cassorla F
    Horm Res Paediatr; 2013; 80(5):343-9. PubMed ID: 24280743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
    Ibáñez L; Valls C; Potau N; Marcos MV; de Zegher F
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3526-30. PubMed ID: 11061495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
    Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
    Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.
    Ibáñez L; Valls C; Ferrer A; Marcos MV; Rodriguez-Hierro F; de Zegher F
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3595-8. PubMed ID: 11502783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Dec; 34(12):1073-1080. PubMed ID: 30044162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin therapy in women with polycystic ovary syndrome.
    Aruna J; Mittal S; Kumar S; Misra R; Dadhwal V; Vimala N
    Int J Gynaecol Obstet; 2004 Dec; 87(3):237-41. PubMed ID: 15548396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
    Adams JM; Taylor AE; Crowley WF; Hall JE
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4343-50. PubMed ID: 15356031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone.
    Bahtiyar G; Weiss K; Sacerdote AS
    Endocr Pract; 2007 Oct; 13(6):601-8. PubMed ID: 17954415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
    Kriplani A; Agarwal N
    J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
    Ibáñez L; Ong K; Ferrer A; Amin R; Dunger D; de Zegher F
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2600-6. PubMed ID: 12788862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progesterone Suppression of Luteinizing Hormone Pulse Frequency in Adolescent Girls With Hyperandrogenism: Effects of Metformin.
    Lundgren JA; Kim SH; Burt Solorzano CM; McCartney CR; Marshall JC
    J Clin Endocrinol Metab; 2018 Jan; 103(1):263-270. PubMed ID: 29095983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
    Ibáñez L; López-Bermejo A; Díaz M; Marcos MV; de Zegher F
    J Clin Endocrinol Metab; 2011 Aug; 96(8):E1262-7. PubMed ID: 21632811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian hyperandrogenism in adolescents and young women with type I diabetes is primarily related to birth weight and body mass index.
    Bizzarri C; Benevento D; Ravà L; Patera IP; Schiaffini R; Ciampalini P; Giannone G; Cappa M
    Fertil Steril; 2011 Dec; 96(6):1497-1502.e1. PubMed ID: 21982726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
    Fux Otta C; Wior M; Iraci GS; Kaplan R; Torres D; Gaido MI; Wyse EP
    Gynecol Endocrinol; 2010 Mar; 26(3):173-8. PubMed ID: 20148739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.